Terminated PHASE3 INTERVENTIONAL 1-arm NCT00174187

Treatment With Recombinant Human Growth Hormone (GH) in Children With Short Stature Secondary to a Long Term Corticoid Therapy

Treatment With Recombinant Human Growth Hormone Genotonorm (Registered) in Children With Short Stature Secondary to a Long Term Corticoid Therapy. A Study of Efficacy and Safety.

Sponsor: Pfizer

Conditions Endocrine System Diseases

Interventions Somatropin

Updated 6 times since 2017 Last updated: Nov 5, 2012 Started: Sep 30, 2000 Primary completion: Sep 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

See termination reason in detailed description.

Other terminated trials from Pfizer

See all terminations from Pfizer

Other Endocrine System Diseases trials with similar outcome

Browse all Endocrine System Diseases trials

A PHASE3 clinical study on Endocrine System Diseases, this trial is terminated or withdrawn. The trial is conducted by Pfizer and has accumulated 6 data snapshots since 2000. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Dec 2021 — Jul 2024 [monthly]

Terminated PHASE3
Jan 2021 — Dec 2021 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Sep 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Paris, France